Showing 1131-1140 of 1395 results for "".
- Automeyes Optical Solutions Receives Patent for its Signature Measurement Technology Benefiting ECPhttps://modernod.com/news/automeyes-optical-solutions-receives-patent-for-its-signature-measurement-technology-benefiting-ecp/2480123/Automeyes Optical Solutions has officially received the patent for the technology behind Automeyes, which was approved by the U.S. Patent Office in February of 2018. Automeyes Founder and creator, Kurt Gardner, was able to prove the methodology was unique and sound enough to receive patent protec
- New Dates Set for Vision Expo East 2021https://modernod.com/news/new-dates-for-vision-expo-east-2021/2478371/The Vision Council and Reed Exhibitions, organizers of Vision Expo, announced that Vision Expo East 2021, originally scheduled to take place from March 18–21, will now take place May 25–28, 2021 (Education: May 25–28; Exhibition: May 26–28) at the Javits Center in New York City. The date change r
- SECO International Names Dr. R. Max Raynor as 2021 Presidenthttps://modernod.com/news/seco-international-names-dr-r-max-raynor-as-2021-president/2477497/SECO International has named R. Max Raynor, OD, as the next president. His term began on March 7, 2020, and will last through February 28, 2021. Dr. Raynor officially accepted the honor during the House of Delegates meeting held on Saturday, March 7 at SECO 20/20. “Dr. Raynor has dedicated
- FDA Issues Third Complete Response Letter to Aldeyra Therapeutics for Dry Eye Drug Reproxalaphttps://modernod.com/news/fda-issues-third-complete-response-letter-to-aldeyra-therapeutics-for-dry-eye-drug-reproxalap/2486097/In another setback for Aldeyra Therapeutics, the FDA issued a third Complete Response Letter (CRL) regarding its new drug application (NDA) for investigational dry eye treatment reproxalap. In the letter, the FDA stated that th
- FDA Issues CRL to Sydnexis for SYD-101 in Pediatric Myopiahttps://modernod.com/news/fda-does-not-approve-sydnexis-syd-101-in-pediatric-myopia/2484210/The FDA has issued a complete response letter (CRL) for Sydnexis' new drug application (NDA) for SYD-101, a proprietary 0.01% atropine formulation designed to slow the progression of myopia in children. T
- Glaukos Receives EU MDR Certification for iStent infinite and iStent inject Whttps://modernod.com/news/glaukos-announces-european-union-mdr-certification-for-istent-infinite-and-istent-inject-w/2482868/Glaukos received European Union (EU) Medical Device Regulation (MDR) certification for iStent infinite, along with several of its other MIGS technologies, including iStent inject W. Glauko
- Nationwide Recall Issued for Multiple OTC Eye Care Productshttps://modernod.com/news/nationwide-recall-issued-for-multiple-otc-eye-care-products/2482809/A voluntary recall for multiple OTC eye care products, including artificial tears and lubricant eye drops, was issued due to serious manufacturing violations identified during an FDA audit. The
- Isarna Therapeutics Presents Positive Phase 2 BETTER Trial Final Resultshttps://modernod.com/news/isarna-therapeutics-presents-positive-phase-2-better-trial-final-results-at-arvo-2025/2482797/Isarna Therapeutics presented final positive results from its phase 2 BETTER trial at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting on May 6. Isarna’s Chief Medical Officer, Prof. Marion R. Munk, shared data
- iStar Medical Announces Positive 5-year Results of MINIject® in Glaucoma Patientshttps://modernod.com/news/istar-medical-announces-positive-5-year-results-of-miniject-in-glaucoma-patients/2482760/iStar Medical has announced positive 5-year results from the STAR-GLOBAL trial for their MINIject®device in patients with open-angle glaucoma. STAR-GLOBAL is an extension trial investigating the long-term safety and efficacy of MINIject® up to five years after im
- Alcon to Acquire Israel-Based Belkin Vision, Maker of Eagle SLT Laserhttps://modernod.com/news/alcon-to-acquire-israel-based-belkin-vision-maker-of-eagle-slt-laser/2482270/Alcon has bolstered its glaucoma surgical portfolio after announcing plans to acquire Belkin Vision in deal potentially worth more than $300 million. The deal, which was first reported by Israel-based business news provider, Globes, has been confirmed by Eyewire+. According